Alnylam’s (ALNY) management simply continues to execute, logging another quarter of better than expected results and moving the pipeline forward. While Covid-19 is going to create some near-term challenges for the Onpattro franchise, it should be recoverable later in the year provided that a renewed surge in infections doesn’t prompt another round of shutdowns. On a more lingering note, though, Covid-19 is creating some trial delays that won’t be recovered, but these aren’t particularly material.
With the shares up roughly 30% from my last article a month ago, I can’t complain about